Gene Therapy Market, 2030

Dublin, May 16, 2018 (GLOBE NEWSWIRE) -- The "Gene Therapy Market (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The Gene Therapy Market (2nd Edition), 2018-2030' report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on the future potential of this evolving market.

The year 2017 was particularly eventful; despite the withdrawal of Glybera from the European market in early 2017, the latter half of the year witnessed the approval of two gene therapies, namely Invossa and Luxturna. In fact, Luxturna became the first gene therapy to gain approval in the US. Further, promising clinical results were reported for several gene therapies that are currently in late phases of development.

The growing popularity and potential of gene therapies can be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 7,300 patents in 2013 to 42,300 patents till the third quarter of 2017. Further, over the past five years, capital worth more than USD 9.8 billion has been invested by venture capital (VC) firms and government bodies to fund research activities in this domain.The overall market is expected to witness significant growth in opportunities for a variety of stakeholders in the coming decade. It is important to highlight that several technology providers, aiming to develop and / or support the development of gene therapies, with improved efficacy and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation in this domain has also led to the discovery of novel molecular targets and strengthened the research pipelines of companies focused in this space. The capability to target diverse therapeutic areas is considered to be amongst the most prominent growth drivers of this market.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2018-2030. To account for the uncertainties associated with the development of gene therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.Key Topics Covered:

1. PREFACE1.1 Scope of the Report1.2 Research Methodology1.3 Chapter Outlines2. EXECUTIVE SUMMARY3. INTRODUCTION3.1. Context and Background3.2. Evolution of Gene Therapy3.3. Classification of Gene Therapy3.4. Routes of Administration3.5. Mechanism of Action of Gene Therapy3.6. Advantages and Disadvantages3.7. Ethical and Social Concerns3.8. Gene Therapy: Affiliated Methods and Technologies3.9. Future Constraints and Challenges3.10. Regulatory Guidelines4. VIRAL AND NON-VIRAL VECTORS4.1. Chapter Overview4.2. Viral Vectors4.3. Types of Viral Vectors4.3.1. Adeno-associated Viral Vectors4.3.2. Adenoviral Vectors4.3.3. Lentiviral Vectors4.3.4. Retroviral Vectors4.3.5. Other Viral Vectors4.4. Non-Viral Vectors4.4.1. Types of Non-Viral Vectors4.4.1.1. Plasmid DNA4.4.1.2. Liposomes, Lipoplexes and Polyplexes4.4.1.3. Oligonucleotides4.4.2. Methods of Transfection4.4.2.1. Biolistic Methods: Gene Gun4.4.2.2. Electroporation4.4.2.3. Receptor Mediated Gene Delivery Methods4.4.2.4. Gene Activated Matrix (GAM)4.5. Applications of Viral and Non-Viral Vectors4.5.1. In Gene Therapy4.5.2. In Vaccinology5. COMPETITIVE LANDSCAPE5.1. Chapter Overview5.2. Gene Therapy Market: Clinical Pipeline5.3. Gene Therapy Market: Preclinical / Discovery Pipeline5.4. Gene Therapy: Key Players5.5. Gene Therapy: Prominent Hubs5.6. Gene Therapy: Regional Landscape6. MARKETED GENE THERAPIES6.1. Chapter Overview6.2. Gendicine (Shenzhen SiBiono GeneTech)6.3. Oncorine (Shanghai Sunway Biotech)6.4. Rexin-G (Epeius Biotechnologies)6.5. Neovasculgen (Human Stem Cell Institute)6.6. Strimvelis (GSK)6.7. Imlygic (Amgen)6.8. Invossa (TissueGene)6.9. Luxturna (Spark Therapeutics)7. LATE STAGE (PHASE II/III AND ABOVE) GENE THERAPIES7.1. Chapter Overview7.2. ASP0113: Overview of Therapy, Key Developments and Clinical Results7.3. Axalimogene Filolisbac: Overview of Therapy, Key Developments and Clinical Results7.4. AVXS-101: Overview of Therapy, Key Developments and Clinical Results7.5. Beperminogene Perplasmid (Collategene): Overview of Therapy, Key Developments and Clinical Results7.6. Donaperminogene Seltoplasmid (VM202): Overview of Therapy, Key Developments and Clinical Results7.7. E10A: Overview of Therapy, Key Developments and Clinical Results7.8. GS-010: Overview of Therapy, Key Developments and Clinical Results7.9. GSK2696274: Overview of Therapy, Key Developments and Clinical Results7.10. GSK2696275: Overview of Therapy, Key Developments and Clinical Results7.11. ImmunoPulse: Overview of Therapy, Key Developments and Clinical Results7.12. Instiladrin: Overview of Therapy, Key Developments and Clinical Results7.13. Lenti-D: Overview of Therapy, Key Developments and Clinical Results7.14. LentiGlobin BB305: Overview of Therapy, Key Developments and Clinical Results7.15. Ofranergene Obadenovec (VB-111): Overview of Therapy, Key Developments and Clinical Results7.16. OTL-101: Overview of Therapy, Key Developments and Clinical Results7.17. Pexastimogene Devacirepvec (Pexa-Vec): Overview of Therapy, Key Developments and Clinical Results7.18. ProstAtak: Overview of Therapy, Key Developments and Clinical Results7.19. Valoctocogene roxaparvovec (BMN 270): Overview of Therapy, Key Developments and Clinical Results7.20. Vigil: Overview of Therapy, Key Developments and Clinical Results7.21. VGX-3100: Overview of Therapy, Key Developments and Clinical Results7.22. Vocimagene Amiretrorepvec (Toca-511): Overview of Therapy, Key Developments and Clinical Results8. EMERGING TECHNOLOGIES8.1. Chapter Overview8.2. Genome Editing Technologies8.2.1. Overview8.2.2. Applications8.3. Emerging Technology Platforms8.3.1. CRISPR / Cas9 System8.3.2. megaTAL8.3.3. TALENs8.3.4. Zinc Finger Nuclease8.4. Gene Expression Regulation Technologies8.4.1. RheoSwitch Therapeutic System8.4.2. Transformative Gene Regulation Technology8.5. Technology Platforms for Developing / Delivering Gene Therapy8.5.1. Gene Mediated Cytotoxic Immunotherapy Technology8.5.2. Innovative Delivery Method8.5.3. Innovative Modular Technology8.5.4. In Situ Delivery and Production System (i-DPS)8.5.5. LentiVector Platform8.5.6. NAV Technology Platform9. THERAPEUTICS AREAS9.1. Chapter Overview9.2. Cardiovascular Disorders9.3. Hematological Disorders9.4. Inflammatory & Infectious Disorders9.5. Metabolic Disorders9.6. Muscular Disorders9.7. Neurological Disorders9.8. Ocular Disorders9.9. Oncology10. FUNDING AND INVESTMENT ANALYSIS10.1. Chapter Overview10.2. Types of Funding10.3. Gene Therapy Market: Funding and Investment Analysis11. COST PRICE ANALYSIS11.1. Chapter Overview11.2. Gene Therapy Market: Factors Contributing to Price Tags11.3. Gene Therapy Market: Pricing Models11.3.1. On the Basis of Associated Costs11.3.2. On the Basis of Competition11.3.3. On the Basis of Patient Segment11.3.4. On the Basis of Experts' Opinion12. PATENT ANALYSIS12.1. Chapter Overview12.2. Scope and Methodology12.3. Gene Therapy Patents: Distribution by Filing Year12.4. Gene Therapy Patents: Distribution by Geographical Location of Patent Offices12.5. Gene Therapy Patents: Distribution by CPC Classification12.6. Gene Therapy Patents: Emerging Areas12.7. Gene Therapy Patents: Leading Players12.8. Gene Therapy Patents: Competitive Benchmarking12.9. Gene Therapy Patents: Valuation Analysis12.10. Gene Therapy Patents: Leading Citations13. MARKET SIZING AND OPPORTUNITY ANALYSIS13.1. Chapter Overview13.2. Forecast Methodology13.3. Overall Gene Therapy Market, 2018-203013.3.1. Gene Therapy Market: Distribution by Therapeutic Area13.3.2. Gene Therapy Market: Distribution by Vector Type13.3.3. Gene Therapy Market: Distribution by Therapy Type13.3.4. Gene Therapy Market: Distribution by Geography13.4. Gene Therapy Market: Product-wise Sales Forecasts13.4.1. Gendicine13.4.2. Oncorine13.4.3. Rexin-G13.4.4. Neovasculgen13.4.5. Strimvelis13.4.6. Imlygic13.4.7. Invossa13.4.8. Luxturna13.4.9. ASP011313.4.10. Axalimogene Filolisbac13.4.11. AVXS-10113.4.12. Beperminogene Perplasmid (Collategene)13.4.13. Donaperminogene Seltoplasmid (VM202)13.4.14. E10A13.4.15. GS-01013.4.16. GSK269627413.4.17. GSK269627513.4.18. ImmunoPulse13.4.19. Instiladrin13.4.20. Lenti-D13.4.21. LentiGlobin BB30513.4.22. Ofranergene Obadenovec (VB-111)13.4.23. OTL-10113.4.24. Pexastimogene Devacirepvec (Pexa-Vec)13.4.25. ProstAtak13.4.26. Valoctocogene roxaparvovec (BMN 270)13.4.27. Vigil13.4.28. VGX-310013.4.29. Vocimagene Amiretrorepvec (Toca-511)14. VIRAL VECTOR MANUFACTURING14.1. Chapter Overview14.2. Manufacturing Viral Vectors14.3. Viral Vector Manufacturing Processes14.3.1. Mode of Vector Production14.3.2. Adherent Cells Versus Suspension Cells14.3.3. Unit Process Versus Multiple Parallel Processes14.3.4. Cell Culture Systems for Production of Different Viral Vectors14.4. Serum-Containing Versus Serum-Free Media14.5. Bioprocessing of Viral Vectors14.5.1. AAV Vector Production14.5.2. Adenoviral Vector Production14.5.3. Lentiviral Vector Production14.5.4. Retroviral Vector Production14.6. Challenges Related to Vector Manufacturing14.7. Companies Offering Contract Services for Viral and Plasmid Vectors14.8. Partnerships14.9. Recent Developments15. CONCLUSION15.1. Gene Therapy Market is Characterized by a Robust Pipeline of Candidates Being Developed Using Various Types of Vectors15.2. Although Product Candidates are Being Developed to Treat a Number of Clinical Conditions, the Primary Focus is on Oncology15.3. Currently, the Market is Led by Big Pharma Players; However, Many Start-ups, Supported by Both Private and Public Investors, are Spearheading Innovation in this Domain15.4. CMOs are Expected to Continue to Play a Key Role in Driving Manufacturing Efforts in the Industry15.5. Given the Advancements in Technology Platforms and the Approval of Late Stage Product Candidates, the Market is poised to Grow Significantly in the Foreseen Future16. INTERVIEW TRANSCRIPTS16.1. Chapter Overview16.2. Adam Rogers, CEO, Hemera Biosciences16.3. Al Hawkins, CEO, Milo Biotechnology16.4. Cedric Szpirer, Executive & Scientific Director, Delphi Genetics16.5. Christopher Reinhard, CEO and Chairman, Cardium Therapeutics16.6. Jeffrey Hung, CCO, Vigene Biosciences16.7. Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager, PlasmidFactory16.8. Michael Triplett, CEO, Myonexus Therapeutics17. APPENDIX 1: TABULATED DATA18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned

• 4BIO Capital
• 5AM Ventures
• Abbott
• Abby Grace Foundation
• Abeona Therapeutics
• Abingworth
• ABL Europe
• Ablynx
• Abraxis BioScience
• Acceleron Pharma
• Acucela (Subsidiary of Kubota Pharmaceutical)
• Adage Capital Management
• Aduro Biotech
• Advanced BioScience Laboratories (ABL)
• Advanced Biotherapeutics Consulting
• Advantagene
• Advaxis Immunotherapies
• Adverum Biotechnologies
• Agent Capital
• Agilis Biotherapeutics
• Ajinomoto Althea
• AJU IB Investment
• Aldevron
• Alexandria Venture Investments
• Allele Biotechnology and Pharmaceuticals
• Ally Bridge Group (ABG)
• Alpha-1 Foundation
• AlphaVax
• Amgen
• AMSBIO
• Anaeropharma Science
• Anemocyte (previously known as Areta International)
• AnGes
• Angionetics
• Apic Bio
• Applied Genetic Technologies Corporation (AGTC)
• Applied Viromics
• ARCH Venture Partners
• Arthrogen
• AstraZeneca
• Athena Vision
• Atlas Venture
• aTyr Pharma
• Audentes Therapeutics
• AveXis
• AVROBIO
• Baillie Gifford
• Bamboo Therapeutics (acquired by Pfizer)
• Batavia Biosciences
• Bayer
• Beckman Research Institute
• Beijing Capital Grand (previously known as Beijing Capital Juda)
• Benitec Biopharma
• BioCanCell Therapeutic
• Biogen
• BioMarin Pharmaceutical
• Biomay
• Biomiga
• BioMotiv
• BioNTech Innovative Manufacturing Services (previously known as EUFETS)
• BioReliance / SAFC
• Bioverativ
• Biovian
• BioViva
• Blue Sky BioServices
• bluebird bio
• BlueWater Angels
• Boehringer Ingelheim BioXcellence
• Boehringer Ingelheim Venture Fund
• Bpifrance
• Brammer Bio
• Bristol-Myers Squibb
• Broad Institute
• Brookside Capital Partners Fund
• California Institute for Regenerative Medicine (CIRM)
• Cambridge Enterprise
• Cancer Prevention and Research Institute of Texas (CPRIT)
• CapDecisif Management
• Caribou Biosciences
• Casdin Capital
• Celgene
• Cell and Gene Therapy Catapult
• Cellectis
• CellGenTech
• Celsion
• Center for the Development of Industrial Technology (CDTI)
• Centre for Process Innovation
• Centre national de la recherche scientifique (CNRS)
• CEVEC Pharmaceuticals
• CHDI Foundation
• Chiesi Farmaceutici
• Children's Medical Research Foundation
• Children's Hospital of Philadelphia
• Children's Medical Research Foundation
• Clarus Ventures
• Clough Capital Partners
• Cobra Biologics and Pharmaceutical Services
• Cold Genesys
• Columbus Venture Partners
• Commercial & External Partnership, Industrial Affairs (CEPiA)
• Copernicus Therapeutics
• Cormorant Asset Management
• Cowen
• Creative Biogene
• CRISPR Therapeutics
• Cure Sanfilippo Foundation
• CureVac
• Cystic Fibrosis Foundation Therapeutics (CFFT)
• Deerfield Management Company
• Dimension Therapeutics (acquired by Ultragenyx Pharmaceutical)
• DNAtrix Therapeutics
• Easton Capital
• EcoR1 Capital
• Editas Medicine
• Elk OrthoBiologics
• Emergent BioSolutions
• Eminent Venture Capital
• enGenes
• Ensysce Biosciences
• Epeius Biotechnologies
• Errant Gene Therapeutics
• Esteve
• Etubics
• Eurofins Genomics
• Eurogentec
• European Investment Bank (EIB)
• Expression Therapeutics
• ExSight Capital
• Eyevensys
• Federal Holding and Investment Company (SFPI-FPIM)
• Fibrocell Science
• Fireman Capital Partners
• FKD Therapies
• Flagship Pioneering (previously known as Flagship Ventures)
• Fondacin Genoma Espaa
• Fondation Sanfilippo Suisse
• Fondazione Telethon and Ospedale San Raffaele
• Forbion Capital Partners
• Foresite Capital Management
• FoxKiser
• F-Prime Capital Partners (previously known as Fidelity Biosciences)
• Franklin Advisers
• Franklin Templeton Investments
• Fred Hutchinson Cancer Research Center
• Freeline Therapeutics
• Friedreich's Ataxia Research Alliance (FARA)
• FUJIFILM Diosynth Biotechnologies
• Fund+
• Fundacin Sanfilippo B
• Fundacin Stop Sanfilippo
• Further Lane Securities
• Gene Medicine Japan (GMJ) / Kobe Biomedical Accelerator
• GeneCure Biotechnologies
• GeneDetect
• GeneImmune Biotechnology
• Genelux
• Genentech
• GeneOne Life Science
• Genethon
• Genexine
• GenIbet Biopharmaceuticals
• Genprex
• GenScript Biotech
• GenSight Biologics
• GenVec
• GlaxoSmithKline
• Global BioTherapeutics
• GlobeImmune
• GO Capital Amorage
• Google Ventures (GV)
• Gradalis
• Green Cross Holdings
• Guangzhou Double Bio-products
• Harvard University
• HealthCap
• Hemera Biosciences
• Herantis Pharma
• Hercules Capital
• Hoffmann-La Roche
• HORAMA
• Horizon Discovery
• Horizon Pharma
• Huapont Life Sciences
• Human Stem Cells Institute
• I2BF Global Ventures
• Ichor Therapeutics
• Ichor Systems
• ID Pharma
• Idinvest Partners
• Immune Technology
• Imperial Innovations
• Inception Capital Management
• Index Ventures
• Innovation Network Corporation of Japan (INCJ)
• Innovative Genomics Institute (IGI)
• Inovio Pharmaceuticals
• Inserm
• Intellia Therapeutics
• Intrexon
• Invesco Perpetual
• InvivoGen
• Ion Channel Innovations
• Iowa State University
• Israel Innovation Authority
• Janssen
• Janus Capital Management
• Jennison Associates
• Johns Hopkins University
• Johnson & Johnson Development Corporation
• JumpStart Ventures
• Juventas Therapeutics
• Kaneka Eurogentec
• Khosla Ventures
• Kiwoom Securities
• Knight Therapeutics
• KOLON LIFE SCIENCE
• Krystal Group
• Kubota Pharmaceutical
• Kurma Partners
• Leerink Transformation Partners
• Leland Stanford Junior University
• Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec)
• Leukon Investments
• Lime Asset Management
• Lonza
• Louisiana State University (LSU)
• Luminous BioSciences
• Lundbeckfonden Ventures
• Lysogene
• Marsala Biotech
• Maryland Technology Development Corporation (TEDCO)
• Massachusetts General Hospital
• Massachusetts Institute of Technology
• MassBiologics
• Medarex
• Medigen Biotechnology
• MedImmune
• Medtronic
• MeiraGTx
• Mercia Technologies
• Merck
• Mercury Fund
• Meridian Life Science
• MERITZ Securities
• MidCap Financial
• Milo Biotechnology
• Miltenyi Biotec
• Mita Securities
• Mitsubishi Tanabe Pharma
• Mitsubishi UFJ Capital
• Moderna Therapeutics
• Molecular Diagnostic Services(MDS)
• MolMed
• MOLOGEN
• Momotaro-Gene
• Morningside Group
• Movember Foundation
• Myonexus Therapeutics
• NanoCor Therapeutics
• NanoDimension Venture Firm
• NantCell
• Nantes Gene Therapy Institute
• National Cancer Institute (NCI)
• National Eye Institute (NEI)
• National Institute of Allergy and Infectious Diseases (NIAID)
• National Institute on Drug Abuse (NIDA)
• National Institutes of Health (NIH)
• National MPS Society
• National Securities Corporation (NSC)
• Nature Technology
• Neuralgene
• Neurotech Pharmaceuticals
• New Energy and Industrial Technology Development Organization (NEDO)
• New Enterprise Associates (NEA)
• New Leaf Venture Partners
• New River Management
• NewVa Capital Partners
• Nightstar Therapeutics
• Nohla therapeutics
• Novartis
• Novartis Venture Fund
• Novasep
• Novo Seeds
• Oberland Capital
• Okairos
• Omega Fund Management
• Omnes Capital
• Omnia Biologics
• Oncolys BioPharma
• OncoSec Medical
• OrbiMed Advisors
• ORCA Therapeutics
• Orchard Therapeutics
• ORI Capital
• Osage University Partners
• Oxford BioMedica
• Oxford Finance
• Oxford Genetics
• PacificGMP (a part of Abzena Group)
• Pangu BioPharma
• Panmure Gordon
• Paragon Bioservices
• Partners Innovation Fund
• Pavilion Capital Partners
• PeriphaGen
• Pfizer
• PhaseRx
• PlasmidFactory
• PNP Therapeutics
• Polaris Partners
• Pontifax
• Posco Capital Partners
• Poseida Therapeutics
• Precision BioSciences
• Profectus BioSciences
• Promethera Biosciences
• PsiOxus Therapeutics
• Puresyn
• Quethera
• RA Capital Management
• RBV Capital
• Red Sanfilippo Foundation
• Redmile Group
• Regeneron Pharmaceuticals
• REGENXBIO
• Relieve Genetics
• Renova Therapeutics
• RetroSense Therapeutics (acquired by Allergan)
• Rev1 Ventures (previously known as TechColumbus)
• REYON Pharmaceutical
• Richter-Helm BioLogics
• Ridgeback Capital Management
• Roche
• Roche Venture Fund
• Rock Springs Capital Management
• Rocket Pharma
• RTW Investments
• Rusnano
• SAB Technology
• Sabby Capital
• San Raffaele Telethon Institute for Gene Therapy (SR-TIGET)
• SanBio
• Sanfilippo Children's Foundation
• Sanfilippo Children's Research Foundation (SCRF)
• Sanfilippo Research Foundation (SRF)
• Sangamo Therapeutics
• Sanofi
• Sanofi Genzyme
• Sanofi-Genzyme BioVentures
• Santen Pharmaceutical
• Sarepta Therapeutics
• Scancell
• Sectoral Asset Management
• Selecta Biosciences
• Seventure Partners' Health for Life Capital fund
• Sham Innovation Sant
• Shanghai Sunway Biotech
• Shenzhen Qianhai Taxus Industry Capital Management
• Shenzhen Sibiono GeneTech
• Shinhan Capital
• Shinsei Corporate Investment
• Shire
• Sigma-Aldrich (now a part of Merck)
• SignaGen Laboratories
• Sino Biological
• SIRION Biotech
• Skolkovo Foundation
• SMS Investments
• Sofinnova Ventures
• Song Hong Fang
• Spark Therapeutics
• Sphera Global Health Care
• SR One (investment arm of GlaxoSmithKline)
• Stratophase
• StrideBio
• SV Life Sciences Investors
• Syncona Partners (a subsidiary of the Wellcome Trust)
• Synpromics
• Synthace
• System Biosciences
• T. Rowe Price
• Takeda Pharmaceutical
• Target ALS Foundation
• Targeted Technology Fund
• Targovax
• Team Sanfilippo
• Tekes
• Temasek Holdings
• Tethys Ventures
• The Finnish Funding Agency for Technology and Innovation
• The French Muscular Dystrophy Association (AFM-Tlthon)
• The Jagen Group
• The Scripps Research Institute
• TheraBiologics
• TheraVectys
• Thermo Fisher Scientific
• Third Rock Ventures
• Third Security
• TissueGene
• Tocagen
• Transgene
• Tufts Financial Group (TFG)
• Turenne Sant
• TVM Capital
• Two Blades Foundation
• UB Securities
• UCL Technology Fund
• UK Innovation & Science Seed Fund (UKI2S, previously known as The Rainbow Seed Fund)
• uniQure
• University of California
• University of Florida
• University of Minnesota
• University of Pennsylvania
• University of Texas
• University of Washington
• Valneva
• Vascular Biologics (also known as VBL Therapeutics)
• VCN Biosciences
• Vectalys
• Vector Biolabs
• Vecura (Karolinska University Hospital)
• Venrock
• Versant Ventures
• Vertex Pharmaceuticals
• VESSL (previously known as MultiGene Vascular Systems )
• Vibalogics
• Vical
• Vigene Biosciences
• Viking Global Investors
• Virginia Biosciences Health Research Corporation (VBHRC)
• ViroMed
• Virovek
• Virttu Biologics (acquired by Sorrento Therapeutics)
• VIVEbiotech
• Vivet Therapeutics
• Vivo Capital
• Voyager Therapeutics
• Waisman Biomanufacturing
• Wellcome Trust
• Wellington Management Company
• Wellstat Ophthalmics
• Whitesun Healthcare Ventures
• WI Harper Group
• Woodford Investment Management
• WuXi AppTec
• XyloCor Therapeutics
• Ysios Capital
• Yuhan
• ZIOPHARM Oncology

For more information about this report visit https://www.researchandmarkets.com/research/c7nm5b/gene_therapy?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Genomics

Source: Research and Markets

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In